• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

    4/9/24 4:05:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ILMN alert in real time by email

    Joydeep Goswami to serve as advisor through June 30

    Illumina reaffirms Q1 2024 and full-year 2024 financial guidance

    SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

    Ankur Dhingra, who will become Illumina's Chief Financial Officer on April 15.

    Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. Dhingra brings a breadth of experience from the life sciences tools, diagnostics, and pharmaceutical industries. He formerly was CFO at Summit Therapeutics Inc. (NASDAQ:SMMT), and prior to that was CFO of CAREDx, Inc. Dhingra spent more than 18 years at Agilent Technologies, most recently as VP, Investor Relations. Before that, he held various finance leadership roles with progressively increasing responsibility, including multiple business unit CFO roles. He brings experience in developing and executing growth and margin improvement strategies, delivering P&L commitments, and driving businesses toward increasing levels of performance. Dhingra has a demonstrated record of success in executing and influencing growth-oriented business strategies, as well as managing global finance and accounting teams. He is a Chartered Accountant and member of The Institute of Chartered Accountants of India.

    Jakob Wedel has been named Chief Strategy and Corporate Development Officer. Wedel joined Illumina in November 2023 as CEO Chief of Staff, leading strategic transformation initiatives. In his new role, Wedel is responsible for driving Illumina's strategic planning, partnerships, and acquisitions. Previously, Wedel was partner at EY's strategy practice, co-leading their global life science practice, and served in roles at McKinsey & Company and Bain & Company. In the early 2000s, Wedel co-founded the Nordic strategy firm QVARTZ, which was later acquired by Bain.

    "I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," said Jacob Thaysen, Illumina CEO. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms. Both are deeply committed to serving our customers and helping Illumina grow."

    Dhingra and Wedel are both relocating to San Diego. They succeed Goswami, who held both the CFO and Chief Strategy and Corporate Development Officer roles since early 2023. Goswami joined Illumina in 2019 to lead strategy and corporate development. He will continue as an advisor to the company starting April 15 and through June 30. He departs the organization on July 1.

    "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions," said Thaysen. "Joydeep will continue with us for several weeks to support a smooth leadership transition."

    The company has reaffirmed its guidance for the first quarter 2024 and full-year 2024, as announced during its fourth quarter 2023 earnings call on February 8, 2024.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Salli Schwartz

    858-291-6421

    [email protected]

    Media:

    David McAlpine

    347-327-1336

    [email protected]

    Jakob Wedel, who will become Illumina's Chief Strategy and Corporate Development Officer on April 15.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-appoints-ankur-dhingra-chief-financial-officer-jakob-wedel-chief-strategy-and-corporate-development-officer-302112206.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN
    $SMMT

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    Illumina Inc.
    $ILMN
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    Illumina Inc.
    $ILMN
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    Summit Therapeutics Inc.
    $SMMT
    7/1/2025$30.00Buy
    UBS
    More analyst ratings

    $ILMN
    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

    The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date. Under an alliance framework with AstraZeneca, Merck, and Eli Lilly and Company leading as founding participants, the Atlas is already in build for a curated set of

    1/13/26 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

    SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025 ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com. Preliminary fourth quarter 2025 results: Revenue of approximately $1.155 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)Ex-China revenue of approximately $1.100 billion, up 7% from Q4 2024 (and on a constant currency basis)GAAP diluted EPS of $2.14

    1/13/26 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

    SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, February 5, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, February 5, 2026. Interested parties may access the live webcast via the Investor Info

    1/12/26 4:07:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    1/12/26 4:01:39 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    1/6/26 7:52:54 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    1/6/26 7:50:20 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:08:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    SEC Filings

    View All

    Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    1/13/26 9:11:40 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Summit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    1/12/26 7:43:04 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    1/8/26 4:39:40 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Summit Therapeutics

    Wolfe Research initiated coverage of Summit Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Summit Therapeutics with a new price target

    Barclays initiated coverage of Summit Therapeutics with a rating of Underweight and set a new price target of $13.00

    9/17/25 8:03:56 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Leadership Updates

    Live Leadership Updates

    View All

    Illumina Appoints Dr. Eric Green as Chief Medical Officer

    Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO  SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di

    1/8/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ILMN
    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Financials

    Live finance-specific insights

    View All

    Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

    SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, February 5, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, February 5, 2026. Interested parties may access the live webcast via the Investor Info

    1/12/26 4:07:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

    Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basisGAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025Repurchased 1.2 million shares of our common stock for $120 million at an average price of $97.10 per shareFor fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (1.5%) to (0.5%), up from (2.5%) to (1.5%)Revenue growth outside of China in the range of 0.5% - 1.5% on a constant currency basis, with no ch

    10/30/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

    Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summit's Global Phase III Development Program Starts with Initiation of HARMONi-GI3, a New Study in 1L CRC: Summit to Initiate an Additional Set of Phase III Clinical Trials with Details to Come in Q1 2026 Ivonescimab with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy with Consistent Data across Regions Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40%, Median PFS of 11.14 Months, Compared

    10/20/25 6:45:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care